LOGIN
Zoledronic acid increases BMD at tibial epiphysis, but not tibial diaphysis
May 2014
Zoledronic acid increases BMD at tibial epiphysis, but not tibial diaphysis
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Cortical bone loss at the tibia in postmenopausal women with osteoporosis is associated with incident non-vertebral fractures: results of a randomized controlled ancillary study of HORIZON
Maturitas. 2014 Mar;77(3):287-93Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
117 postmenopausal women who were enrolled in the HORIZON trial were recruited for this ancillary study which investigated the effect zoledronate (ZOL) on bone mineral density (BMD) of the tibia. This study measured tibial epiphsyis and tibial diaphysis BMD at 12, 24, and 36 months, and compared results to a group treated with placebo (PBL group). Results on tibial epiphysis BMD indicated an incre...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.